Deepak Bhatt, MD, believes bentracimab could be a game-changer if it gains approval. "I think it's the sort of drug that every emergency room and ICU would have to stock," he said. "A cardiac care unit would have to stock a couple of doses, as would every cath lab."
Providers are up to three times more likely to trust the opinion of humans over AI, even when the algorithm is proven to detect more cancerous lesions than radiologists.
Raj Makkar, MD, Cedars-Sinai, explains the late-breaking data from the Align-AR trial on the first 500 patients treated for aortic regurgitation using the Jena Valve TAVR device.
A machine learning system has come along that needs no human labeling of data for training yet matches radiologists at classifying diseases on chest X-rays—including some that the model was not specifically taught to detect.
A new analysis published in Radiology details signs of persistent pulmonary dysfunction in children who have recovered from a COVID infection or who are experiencing symptoms of long-COVID.
Comparison between transcatheter edge-to-edge repair (TEER) devices found Pascal was non-inferior compared with MitraClip in the CLASP IID pivotal trial.
The UNIVERSAL Trial, one of the largest multicenter randomized trials comparing ultrasound with fluoroscopic guidance vs. fluoroscopic guidance alone, found there was no reduction in major vascular access complications.
Insured or not, few Americans are immune to medical debt. And when a budget-busting event comes, it can significantly worsen such basic social determinants of health (SDOH) as housing security and food affordability.
The PROTECTED TAVR results presented at TCT 2022 resulted in a mix of reactions. For some cardiologists, the slight reduction in the risk of a disabling stroke after TAVR is a positive result. For others, it was simply not enough.
This is the second FDA-cleared transcatheter repair device for the mitral valve. Data from pivotal trial comparing Pascal vs. MitraClip will be presented at TCT 2022.
